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ABSTRACT 
A technique is described which couples High Performance 
Liquid Chromatography (HPLC) to radioimmuno assays (RIA) , thus 
achieving high sensitivity with good specificity. This method 
allows the separation and detection of multiple forms of immuno- 
reactive peptides. Using this procedure, we have characterized 
the B-E-like immunoreactivity in rat pituitary. It had been 
previously reported that most of the B-E-sized material in both 
intermediate and anterior lobe of rat pituitary is not true 
B-El_31. We now report that N-acetyl B-El-27, which is inactive 
at the opiate receptor, is indeed the predominant peptide in rat 
intermediate lobe, with B-El-31 representing a low proportion of 
the immunoreactivity. On the other hand, the opiate active 
B-ENDl_31 is the predominant peptide in the anterior lobe. These 
findings have important implications for the physiological and 
behavioral roles of the pituitary opioids. 
INTRODUCTION 
The multiplicity of endogenous opioids is becoming increas- 
ingly apparent. Several anatomically distinct opioid systems 
have been described in brain, pituitary and peripheral tissues. 
These include methionine and leucine enkephalin containing 
pathways (1,2), the pro-opiocortin networks in the brain and 
pituitary (3,4,5) and the recently discovered peptides dynorphin 
and alpha-neo-endorphin which contain at their N-terminal the 
structure of leucine enkephalin (6). The picture is further com- 
plicated by the presence of stored and potentially releaseable 
precursors, such as beta-Lipotropin (B-LPH) the precursor of 
B-Endorphin (B-E) (7,8), and of biologically active product, such 
as alpha or gamma Endorphin (9). Moreover, the work of Smyth and 
Zakarian (10) has shown the existence of N-acetylated forms of 
B-E, which exhibit little or no opiate activity but cross react 
with B-E antisera. Swann and Li (11) have also described B-E 
like immunoreactivity in brain with an amino-acid composition 
different from B-E (47% discordance) and little opiate activity. 
This multiplicity renders it difficult to carry out meaningful 
physiological/biochemical studies using only bioassays since 
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several of these substances occur in the same structures and 
interact with opiate receptors. It is equally difficult to 
exclusively rely on rad ioimmunoassays since cross-reactivity, 
even if minimal, can become a significant issue if behavioral 
manipulations affect one or the other cross-reacting peptide dif- 
ferentially. It is therefore critical to couple such procedures 
as radioreceptor assays (RRA) or radioimmunoassays (RIA) with 
reliable chromotographic steps which separate the various pep- 
tides. 
At a more theoretical level, it is critical to determine the 
relative concentrations of “true” B-E in various tissues, since 
this would greatly affect interpretation of physiological and 
behavioral studies. According to Zacharian and Smyth (10) little 
authentic B-E is present in rat pituitary, suggesting that 
material released upon stress along with ACTH (12) is not opiate 
active. 
We therefore sought to establish a procedure which would 
reliably separate the various species of opioid and related pep- 
tides, and which could be employed easily in extracts from single 
animals in order to permit assay of specific levels after physio- 
logical, pharmacological or behavioral manipulations. The 
criteria were as follows: a) precision and power to separate the 
critical form of opioid peptide, especially those similar in 
molecular weight and in amino acid sequences. b) reliability to 
permit comparison between small groups of animals. c) very high 
sensitivity since the concentration of these peptides in brain 
can be very low - e.g. less than 100 pmoles of B-E in whole rat 
brain, and less than 100 fmoles/ml in normal rat plasma. d) good 
recovery across a wide range of levels, since experimental mani- 
pulation could cause alterations by several orders of magnitude. 
e) speed in order to process numerous experimental samples. 
The use of high performance 1 iquid chromatography (HPLC) 
offered the advantages of precision and power, speed and reli- 
ability. This technique had been used for purification of syn- 
thetic peptides, as well as for large scale extraction, purifi- 
cation and identification of peptides (11,13,14,15). However, in 
most of these procedures extremely high sensitivity was not an 
important issue nor was high recovery of very small quantities. 
Thus, Gentleman et al (16) have described a rapid purification 
method for B-E but good recovery is not seen below 10 nmoles. In 
his excellent paper on the use of triethylamine-containing phos- 
phate buffer to improve recovery, Rivier (17) reports a detection 
limit by UV of 50ng - which would be equivalent to about 15 
pmoles of B-E. The use of fluorescence detection (14,lS) does 
improve the sensitivity to the low pmole range. However, these 
detection limits are far below those possible with RIA which can 
detect in the low fmole range - i.e. at least one hundred fold 
better (18). It seemed desirable to couple HPLC precision with 
RIA sensitivity in an attempt to achieve both of the 
above-specified criteria. Aside from being potentially more 
sensitive, this approach would permit the detection of multiple 
species of peptides for which there are no commercially available 
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standards - such as the acetylated forms of rat B-E, or the 
authentic form of dynorphin (not yet completely sequenced) . A 
few other investigators have employed such an approach in the 
study of opioids and related peptides with good success - e.g. to 
identify and quantitate multiple forms of a-MSH (19,20), or to 
measure the metabolites of B-E (9). We have extended these 
sepration and quantitation methods to include the coupling of 
HPLC with opiate radio-receptor assay (RRA) to determine whether 
an immunoreactive peak also possesses opiate activity. 
One difficulty inherent in this technique lies in the inter- 
facing of HPLC with RIA or RRA. Since we shall be dealing with 
small quantities of peptides, little dilution would occur when 
moving from chromatography to bioassay. Thus, any non-specific 
effect, e.g. from the buffer or solvents may alter the RIA or RRA 
and lead to either false positives or false negatives. The fol- 
lowing is a description of a system which meets the criteria set 
forth above, and minimizes non-specific effects of HPLC on RIA 
and RRA. This procedure is currently in use for assay of 
numerous opioid and related peptides. We report here its appli- 
cation to study B-E immunoreactivity in anterior and intermediate 
lobe of rat pituitary, and suggest that, in anterior lobe, a 
large proportion of the immunoreactivity is indeed associated 
with the opiate active form of B-E. 
METHODS 
Extraction of peptides: The majority of the studies 
carried out on rat pituitary and hypothalamus, although 
species - such as monkey - and other tissues and samples - 




Animals are sacrificed by decapitation and the brain or 
pituitary rapidly extracted and dissected. They are then immedi- 
ately frozen on dry ice, and stored at -5O’C. 
The extraction procedure consists of homogenizing the tis- 
sue in an ice cold mixture of Acetone: 2N HCl (3:l) containing 
33 ul/ml of a solution of peptidase inhibitors. The solution of 
inhibitors consists of 30 mg/ml of phenylmethylsulfonyl fluoride 
and iodoacetamide dissolved in absolute alcohol. The homogenate 
is spun down at 35,000 x g x 10 min. The supernatant is col- 
lected in plastic tubes and the acetone is evaporated under a 
stream of N2. The material remaining in HCI is then subjected to 
an organic extraction to remove the lipids. Five volumes (v:v) 
of ethylacetate:ether (3:l) are added to the extract, the mixture 
is vortexed and spun at low speed (2000 rpm) for 10 minutes. The 
top lipid-containing phase is discarded, and the 
peptide-containing phase is evaporated in a Savant Speedvac 
concentrator, suspended in the appropriate volume of .2N HCI and 
10-40 lJ1 are applied onto the HPLC column. Recovery for extrac- 
tion has been examined by adding both unlabelled and labelled 
peptides, including B-E, a-MSH, Leucine-enkephal in and 
methionine-enkephalin. In all cases, it exceeded 85%. 
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High Performance Liquid Chromatography (HPLC) 
The apparatus consists of the Beckman (Altex) programmable 
system with the 9420 programmer microprocessing unit, two 1lOA 
pumps, a Hitachi 100-40 multiwave length detector and a Kipp & 
Zonen B D 41 chart recorder. All reverse phase chromatography is 
carried out on Beckman ultrasphere ODS columns. 
Several buffer systems, gradient profiles and separation 
conditions were employed before determining the optional set of 
conditions for our requirements. The conditions most commonly 
used consist of a sodium phosphate buffer (SOmM, pH 2.7) con- 
taining .05% triethylamine (cf 17) as solvent A, and 100% aceto- 
nitrite (CH3 CN) as solvent B. The flow rate is typically 
1 ml/min. The most commonly employed gradient program is 
depicted in Fig. 1. Percentage of acetonitrite is raised to 20% 
in 2 minutes, left constant for 2 minutes, then raised to 45% in 
25 minutes, where it remains for another 2 minutes, before 
returning to 5% in 2 minutes for a total duration of 33 min./run. 
b This gradient profile allows eluti n of most of the peptides 
under study. However, it can readily be altered in the interest 
of better separation or speed when the peptides being run are 
known to elute at specific points along the gradient. 
Other variations include changing the sodium phosphate buf- 
fer strength between 30 to 50 mM. While higher concentrations 
produce sharper resolution, lower concentrations lead to less 
interference with some of the RIA's, especially when the tissue 
contains relatively low levels of peptides, and the fractions are 
not highly diluted. We have also employed potassium phosphate 
(30-50mM) rather than sodium phosphate buffer as solvent A, when 
opiate binding 'assays were to be conducted in the absence of 
sodium. 
In all cases, the buffers and solvents are prepared ac- 
cording to Rivier (17), using HPLC-grade materials, and filtering 
aqueous buffers through 0.45 Millipore filter. All HPLC 
procedures are carried out at room temperature. 
Pure peptide standards (0.5 - 1.0 nmole) are injected in 
lo-40 p liter volume, and monitored at 210 nmeter. The effluent 
from the Hitachi monitor is collected in 0.5ml fractions and 
subjected to radioimmunoassay. Radioactive peptides (10,000 - 
200,000 DPM) are similarly treated and the fractions counted 
with beta or gamma scintillation counters as appropriate. Tis- 
sue extracts prepared as described above are also injected in a 
10-40 111 volume, monitored at 210 nmeter and the fractions 
evaporated either in a vacuum oven (room temperature) or in a 
Savant evaporator, resuspended in the appropriate buffer at the 
proper dilution, and subjected to RIA. 
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Peptide Materials Used for HPLC 
These include synthetic human B-E (Bachem) alpha MSH 
(Organon, Ciba-Geigy) des Acetyl MSH (Organon, Ciba Geigy) , 
methionine, and Leucine enkephalin (Bachem) , oxytocin, vasopres- 
sin, dynorphinl-13 (Peninsula Labs), beta Lipotropin (courtesy of 
Dr. C. H. Li, U.C. San Francisco) . The camel forms of B-E, 
N-acetylated B-El-31 (NA -B-El-31), 
(Peninsula Labs) and humag B-E 
B-El-27, NAc-B-El-2 7 
l_31 (National Institute of Mental 
Health) , as well as human (in collab ration with 
Dr. David 
Dr C.H. Li), 
Cgy) l 
NAc-B-El-31 
Radioactive peptides include s H-B-E (from 
H met- and Leu-Enkephalin (New England Nuclear) , as 
well as iodinated peptides labelled within our laboratory. 
Radioimmunoassavs: 
Several RIA’s were used to validate the method and quanti- 
tate the tissue extracts. These include assays to Leucine- 
Enkephal in, methionine-enkephalin, (Final antibody dilution 
1:lOOO) and B-E (final dilutions ranging from 1:3000 to 1:50,000) 
These sera have beentaised by us. 
The general conditions for the enkephalin assays (21) and 
the B-E assay (18) are similar to conditions previously 
described. We have also employed Dr. Vaudry’s a-MSH antisera (cf 
22) and Dr. A. Goldstein’s dynorphin RIA (23) and followed their 
suggested conditions. In some cases we have found it necessary 
to alter the strength or pH of the RIA buffer in order to 
interfacing with 
permit 
HPLC, as will be described below. All assays 
were carried out in 0.25ml volumes. Labelled peptides were added 
in the range of 8-20,000 dpm/tube, 
hours to 72 hours at 4’C. 
and incubations carried for 24 
RESULTS 
Two aspects of the results will be presented here. The 
first relates to the characterization 
approach to endorphins 
of the HPLC/RIA coupled 
and related peptides, and the second 
focuses on 
pituitary. 
the multiplicity of B-E-like immunoreactivity in rat 
1. Characteristics of this HPLC/RIA Procedure: 
At the simplest level, Figure 1 depicts the known power of 
HPLC for separating the peptides which vary slightly in their 
structure but have the same molecular weight. Thus, human B-E is 
clearly more hydrophobic than camel B-E (which is thought to have 
the same structure as rat B-E). The same gradient profile also 
separates a-MSH from des-acetyl a-MSH, an important capability 
since both forms are present in brain (19,20), and are centrally 





Retention Time (min) 
Figure 1: HPLC separation of a-MSH (N-acetyl ACTHl_13 amide) 
from des-acetyl-a-MSH (ACTH 
A713 
amide). Peak 1: des-acetyl- 
a-MSH. Peak 2: a-MSH. Gra lents begins at right of figure, 
at 5% acetonitrite and rises in stages, to 45% acetonitrite. 
lnmole of peptide injected. 
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ficity of radioimmunoassays and radio-receptor assay and would 
permit the detection of opiate activity in other parts of the 
profile not clearly associated with a fully sequenced opioid. 
The question of whether retention time is altered in the 
presence of tissue extract was addressed by injecting on several 
occasions, 3H-B-E (from Dr. C.H. Li) in the presence and absence 
of such extracts. The retention time for the radioactive peptide 
remained constant regardless of the condition. Furthermore, 
3H-B-E was added to tissue at the onset of extraction, and at the 
end of the procedure chromatographed on HPLC. The retention time 
was unaltered compared to untreated 3H-B-E. Thus, there was no 
evidence of oxidation, acetylation or non-specific binding taking 
place throughout the experimental protocol. 
Recovery was also estimated using various radioactive pep- 
tides. Without TEA, recovery was poor and highly variable. How- 
ever, in the presence of TEA the recovery of 3H-B-E varied 
between 95 and 100%. The full range of peptide concentrations 
could be assessed by running 3H-B-E, or iodinated B-E (or other 
peptides) alone, in the presene of millimolar concentration of 
synthetic B-E, or in the presence of tissue extracts. Here 
again, recovery remained excellent across all conditions even 
when we 123ployed as little as 20,000 dpm of 3H-B-E, or 100,000 
DPM of I-B-E. Given the high specific activity of the 
iodinated material (500-1000 ci/mmole) , the amount used 
corresponds to 50 fmoles of B-E. In spite of the excellent 
recovery, the small amount of unrecovered peptides can produce a 
significant artifact if not completely eluted. For example, if 
one employs 1 nmole of authentic unlabelled peptide (e.g. B-E) as 
a standard and recovers 99% of it, the adsorbed 1% still 
represents 10 pmoles of peptides remaining on the column, which 
can be eluted upon later runs. This amount is equivalent to the 
total immunoreactive content of a rat hypothalamus, and can 
easily lead to artifactual quantitation in biological samples. 
If such high amounts of standard peptides are used for cal i- 
bration, we recommend extensive washing of the column and a 
“blank” run with no sample added, in order to ascertain the 
absence of any contamination. Alternatively, small quantities of 
radioactive peptides can be used prior to injection of biological 
samples. We now inject a radioactive marker prior to loading the 
sample , and run our peptide standards after the biological 
samples have been eluted, in order to avoid any possible contami- 
nation. 
Finally the reliability of the systems was tested by esti- 
mating the B-E-like immunoreactivity (HPLC/RIA) in rat neuro- 
intermediate lobe or anterior lobe on at least 5 different 
occasions. Our estimates of total B-E-like 
varied by less than 10% 
immunoreactivity 
In interfacing the HPLC generated fractions with RIA’s we 
required that the solvents per se, throughout the gradient, would 










0.1 1.0 10 100 nM 
Concentration of Unlabelled Peptide 
Figure 2: Radioimmunoassay comparing immunoreactive poten- 
cies of the acetylated and non-acetylated forms of the human 
B-E, and other opioid peptides. Note close correspondence 
at low concentrations, and non-parallelism at high concen- 
tration, suggesting N-terminus directed low affinity popula- 
tion of antibodies. The absence of a C-terminus-directed 
population is indicated by the lack of inhibition of binding 
when the C-terminus tetrapeptide (B-E27_31) is employed. Thus, 
B-El-27 shows the same 
shown but confirmed). 
cross reactivity as B-El-31 - (not 
436 
100 
0 NacC’ *60 Q1 
s 
V 
20 10 8 6 4 
Retention Time (min) 
Figure 3: Partial separation of the 4 forms of B-E-like material 
on HPLC - peptides (500pmoles each) were premixed and injected in 
acetic acid. 
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interactions. When 50mM sodium-phosphate buffer (pH 2.7) was 
evaporated, resuspended in the B-E RIA buffer (10 mM sodium phos- 
phate, pH 7.6) and assayed, a great deal of non-specific 
inhibition was observed. This non-specific inhibition was found 
to be due to the remaining acidity in the HPLC fractions, even 
after complete evaporation, leading to a decrease in the final pH 
of the RIA samples. The problem was handled by two changes: a) 
decreasing the strength of the HPLC sodium-phosphate buffer from 
50mM to 30-40 mM. b) increasing the strength of the RIA buffer 
to 150mM, and the pH of that buffer to 5.2. These changes caused 
little problem for either HPLC or RIA, and resulted in complete 
elimination of the non-specific inhibition in the B-E RIA. 
Similar alterations in alpha-MSH RIA conditions and dynorphin RIA 
conditions and the opiate radio-receptor assay have led to the 
same situation. In general, it is necessary to determine a pH 
“window” for any RIA or receptor assay (i.e. a range which 
produces good binding), as well as the strongest buffer the assay 
can tolerate. Then one can use that buffer at the highest accep- 
table pH for resuspending the samples and maintaining them within 
the correct pH range. 
Thus, the HPLC-RIA system described here yields good 
separation between peptides, excellent recovery in the fmole 
range, in the presence or absence of tissue extracts. It appears 
reliable, and is devoid of the problems of non-specific inhibi- 
tion, yielding no false positives or negatives. 
2. Multiplicity of B-E Immunoreactivity in Pituitary and Brain 
Zakarian and Smyth (10) have reported that B-E is stored in 
both active and inactive forms. They described the existence of 
‘I true” B-E or B-LPH61_glwhich they had termed the C fragment, a 
C’ fragment or B-El-27, and the N-acetylated forms of these two 
peptides. All.but the C fragment (B-El-31) exhibit greatly 
decreased opiate potency. They suggested that the majority of 
B-E-like immunoreactivity both in intermed iate and anterior 
pituitary is not B-El-31, whereas in the hypothalamus it is 
mostly B-EI_31. 
We have employed the HPLC/RIA procedure in order to separate 
multiple B-E-like species in various tissues. It should be noted 
here that (B-EI_~~) and the acetylated form of B-El-31 and of 
B-El-27 were not available when we began our experiments which 
has prevented us and others from using them as standards. We 
have since obtained these compo und s , and used them to identify 
the immunoreactive peaks, as described below. The 
characteristics of the B-E RIA employed are displayed in Fig. 2. 
The separation of the multiple forms of B-E is shown in Fig. 3. 
When rat neurointermediate/posterior lobes are extracted, 
applied to HPLC using our standard gradient then subjected to RIA 
the pattern in Figure 4 emerges. It is apparent that multiple 
species of END immunoreactivity ,-r.are present. None of the 
additional peaks are due to B-LPH, since molecular sieving 
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Figure 4: Immunoreactive profile of rat neuro-intermediate lobe 
after HPLC. 
NAc B-El++ 
Peaks I, II, II are identified as B-E1,31, 
and NAc B-E1_27 respectively. 
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procedures (Biogel PlO, 0.9x50 cm) were carried out first and 
show that only a very small percentage of the intermediate lobe 
immunoreactivity is due to this peptide. Only B-E-sized material 
was applied to the chromatograms shown here. Fig. 4 demonstrates 
that the immunoreactive peak corresponding to authentic B-El-31 
constitutes a very small proportion of the immunoreactivity. The 
major peak (peak 3) is associated with the retention time of 
NAc-B-El-27 (NAcC’). Peak 2 comprises NAc-beta-ENDl-31 (NAcC) 
although in this procedure B-El-27 runs very close. However, 
other work in our laboratory using the ion exchange procedure of 
Zakarian & Smyth (10) with S-P Sephadex and a NaCl gradient shows 
that little or no B-El-27 (Cl) is evident in rat intermediate 
lobe. Thus, peak 1 is B-El-31, peak 2 is NAc-B-El-31, peak 3 is 
NAc-B-El_27, peaks 4 and 5 remain unidentified and may represent 
further processing of the third peak. Peak 4 in particular is a 
highly reliable finding in posterior/intermediate lobe, and is 
not seen in anterior lobe extracts. Further work on the HPLC 
conditions is being carried out to effect a better separation 
between NAc B-El-31 and B-El-27, in order to confirm our findings 
that little C’ is present in intermed iate lobe. The multiple 
immunoreactive peaks in posterior/neuro-intermediate lobe are not 
extraction artifacts since other tissues do not ex bj ibit a similar pattern as will be described below. Furthermore, H-B-E added at 
the start of extraction of this lobe, emerges as a single 
radioactive peak at the end of the extraction. It should be 
noted here that the total immunoreactivity here is 600-700 
pmoles/intermediate pituitary, a concentration consonant with 
total levels obtained prior to HPLC. In these assays, only l/40 
of a posterior neurointermediate lobe is needed to measure all 
the peaks. 
When anterior lobe is dissected with no particular attention 
to a clean separation from posterior/intermediate lobe, the 
identical multiple peaks emerge. However, the total amount of 
B-E immunoreactivity is approximately tenfold higher in inter- 
mediate/posterior lobe than in anterior lobe. Immunohistochemi- 
cal studies show it to be entirely localized in a thin band of 
the neurointermediate pituitary, while it is highly heterogeneous 
in the anterior pituitary (Bloom, 1977) . Thus, the extremely 
high concentration in intermediate lobe makes it easy to contam- 
inate the anterior lobe dissection and lead to spuriously high 
levels and an erroneous pattern. We then dissected anterior lobe 
more carefully, and subjected the extracts to sieving on Sephadex 
G50 or Biogel PlO., and the B-E sized material was appl ied to 
HPLC then assayed. The B-E immunoreactivity emerged in two 
peaks, with the major one chromatographing with authentic B-E 
(Fig. 5). The B-LPH sized material was also collected from the 
sieving step, and appl ied to HPLC. A single peak (Fig. 6) 
emerged which was more hydrophobic than B-E, and which reacted 
with a B-LPH RIA (5). Unfortunately, no standard is available 
for this peptide. It is, however, thought to differ from the 
known structures of B-LPH, and our own results along with others 
(25) show it to have a smaller molecular weight than human B-LPH. 
HPLC, however, coup1 ed with sieving and immunoaff inity columns 
440 
fraction number 
Figure 5: Immunoreactive profile of rat anterior lobe following 
HPLC. Extracts were first sieved on Biogel P 
go* 
The B-E-sized 
material was then applied to HPLC as describe in the text. 
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Figure 6: Tmmunoreactive profile of B-LPH-sized material 
collected from PlC and applied to HPLC. 
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provides, in our hands a rapid and efficient partial purification 
of rat B-LPH for marking purposes. 
DISCUSSION 
The present results support the feasibility of a coup1 ed 
HPLC/RIA approach to studying peptides in individual animals. 
They also point to the real need for such an approach since 
multiple peaks of B-E immunoreactivity emerge in pituitary 
tissue, several of these possessing some opiate receptor 
activities. While some of the peaks remain to be completely 
identified, it is at least possible to single out a specific peak 
which does co-chromatograph with B-E, its acetylated form or the 
N-acetyl C I peak and possess equimolar immunoreactivity and 
partial opiate receptor activity (Akil et al., submitted). This 
would permit more believable measurement of these peptide under 
various treatment conditions such as stress, pharmacological or 
behavioral manipulations. 
The present findings are in partial agreement with Smyth and 
Zakarian’s work (10) suggesting that authentic B-E represents 
only a small proportion of the material in the intermediate lobe 
- in our hands less than 10%. On the other hand, we find that in 
rat anterior lobe, a peak which co-chromatographs with B-E 
represents a substantial proportion of the total immuno- 
reactivity. More recent evidence from Smyth & Zakarian (26) is 
consistent with this view, suggesting that in another species, 
the pig, acetylation is rather uncommon in anterior lobe. Mains 
& Eipper (27) using an ion exchange column also concur in finding 
a high proportion of B-E in anterior pituitary and not in the 
intermed iate lobe. Another area of disagreement revolves around 
the nature of the major peaks in intermediate lobe. In our 
hands, NAc-B-El_27 is the most common product, followed by a more 
hydrophobic material (peak 4) and NAc-B-E. This is in 
contradiction with the older findings of Smyth and Zakarian in 
rat (10) and the more recent ones in pig (26) suggesting 
to be a major constituent. 
B-E1-27 
Taken together, our results strengthen the notion that 
processing of pro-opiocortin in different tissues such as 
intermediate and anterior lobe is quite different. The existence 
of B-E is anterior pituitary would render it available for 
co-release with ACTH, suggesting that a biologically active 
opioid, rather than an inactivated form, would circulate in the 
bloodstream and find its way to various target tissues. The 
predominant intermediate lobe material (NAc-B-E1_27), being 
highly processed, appears to be over 1000 fold less active at the 
opiate receptor (Akil et al.; submitted), non-opiate functions 
should be considered for this molecule. Brain, which makes a-MSH 
from ACTH, may partially process B-El-31 into shorter and 
deactivated forms. The ratio5 of these forms may vary under 
different biological conditions - an area of important 
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